A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma

被引:74
作者
Fuchs, CS
Clark, JW
Ryan, DP
Kulke, MH
Kim, H
Earle, CC
Vincitore, M
Mayer, RJ
Stuart, KE
机构
[1] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
[3] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA
[4] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA
关键词
hepatocellular carcinoma; gemcitabine; chemotherapy; Phase II trial;
D O I
10.1002/cncr.10607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. There is no effective systemic therapy for patients with hepatocellular carcinoma. A recent trial reported a moderate antitumor activity for gemcitabine among Asian patients with advanced hepatocellular carcinoma. This led to our examination of the efficacy and tolerability of the drug in a population of U.S. patients. METHODS. Thirty patients with measurable, unresectable, or metastatic hepatocellular carcinoma who had received at least one previous form of systemic therapy were enrolled. All patients were required to have adequate major organ function 4 and performance status. Patients received gemcitabine (1000 mg/m(2) intravenously over 30 minutes weekly) for 3 consecutive weeks followed by a 1-week rest. Patients were assessed radiographically every 8 weeks. RESULTS. All 30 patients were evaluable for response and toxicity. Ninety cycles of 2 therapy were administered (median 2, range 1-8). No complete or partial responses were observed. Nine patients (30%) had stable disease (median duration 7.4 months, range 2-17). Median survival for all 30 patients was 6.9 months (95% confidence interval, 4.5-13.5) and the 1-year survival rate was 40%. Mild hematologic toxicity occurred. Two patients (7%) developed Grade 4 neutropenia and one patient (3%) experienced Grade 3 thrombocytopenia. There were no episodes of febrile neutropenia. One patient who had previously undergone orthotopic liver transplantation developed hemolytic-uremic syndrome that resolved with discontinuation of chemotherapy and plasmapheresis. CONCLUSIONS. Although generally well tolerated, gemcitabine had minimal effect in patients with advanced hepatocellular carcinoma. (C) 2002 American Cancer Society.
引用
收藏
页码:3186 / 3191
页数:6
相关论文
共 26 条
[1]   Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients [J].
Chao, Y ;
Chan, WK ;
Birkhofer, MJ ;
Hu, OYP ;
Wang, SS ;
Huang, YS ;
Liu, M ;
Whang-Peng, J ;
Chi, KH ;
Lui, WY ;
Lee, SD .
BRITISH JOURNAL OF CANCER, 1998, 78 (01) :34-39
[2]   MDR1 (MULTIDRUG-RESISTANCE) GENE-EXPRESSION IN HUMAN PRIMARY LIVER-CANCER AND CIRRHOSIS [J].
CHENIVESSE, X ;
FRANCO, D ;
BRECHOT, C .
JOURNAL OF HEPATOLOGY, 1993, 18 (02) :168-172
[3]   Rising incidence of hepatocellular carcinoma in the United States [J].
El-Serag, HB ;
Mason, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :745-750
[4]  
Fong Y, 2001, CANC PRINCIPLES PRAC, P1162
[5]  
Fung MC, 1999, CANCER-AM CANCER SOC, V85, P2023
[6]   Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2′,2′-difluorodeoxycytidine on human hepatoma HepG2 cells [J].
Graziadei, I ;
Kelly, T ;
Schirmer, M ;
Geisen, FH ;
Vogel, W ;
Konwalinka, G .
JOURNAL OF HEPATOLOGY, 1998, 28 (03) :504-509
[7]   Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine [J].
Haberkorn, U ;
Bellemann, ME ;
Brix, G ;
Kamencic, H ;
Morr, I ;
Traut, U ;
Altmann, A ;
Doll, J ;
Blatter, J ;
Kinscherf, R .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (04) :418-425
[8]  
Jiang WQ, 1997, CLIN CANCER RES, V3, P395
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]  
Kubicka S, 2001, HEPATO-GASTROENTEROL, V48, P783